Fate Therapeutics, Inc. (FATE) earnings
Fate Therapeutics, Inc. (FATE) reported net income of -$136.32M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$186.26M. Figures as of 18 Nov 2026, 01:09 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Earnings (net income), fiscal 2025
- -$136.32M
- Highest on record
- -$7.17Mfiscal 2008
- Lowest on record
- -$281.72Mfiscal 2022
- Fiscal years on record
- 182008–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Fate Therapeutics, Inc. earnings, in more detail
Across the 18 fiscal years on record (2008–2025), the highest was -$7.17M in fiscal 2008 and the lowest -$281.72M in fiscal 2022.
Earnings (net income) by fiscal year
Fate Therapeutics, Inc. earnings, year by year
| Fiscal year | Earnings (net income) | Change | Year ended |
|---|---|---|---|
| 2025 | -$136.32M | — | |
| 2024 | -$186.26M | — | |
| 2023 | -$160.93M | — | |
| 2022 | -$281.72M | — | |
| 2021 | -$212.15M | — | |
| 2020 | -$173.39M | — | |
| 2019 | -$98.15M | — | |
| 2018 | -$66.60M | — | |
| 2017 | -$42.95M | — | |
| 2016 | -$33.46M | — | |
| 2015 | -$29.99M | — | |
| 2014 | -$25.88M | — | |
| 2013 | -$20.89M | — | |
| 2012 | -$14.24M | — | |
| 2011 | -$13.43M | — | |
| 2010 | -$16.22M | — | |
| 2009 | -$13.33M | — | |
| 2008 | -$7.17M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
How to read it
Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.
Fate Therapeutics, Inc., figure by figure
- Fate Therapeutics, Inc. market cap
- Fate Therapeutics, Inc. revenue
- Fate Therapeutics, Inc. earnings per share (EPS)
- Fate Therapeutics, Inc. P/E ratio
- Fate Therapeutics, Inc. P/S ratio
- Fate Therapeutics, Inc. P/B ratio
- Fate Therapeutics, Inc. free cash flow
- Fate Therapeutics, Inc. operating margin
- Fate Therapeutics, Inc. dividend
- Fate Therapeutics, Inc. shares outstanding
- Fate Therapeutics, Inc. total debt
- Fate Therapeutics, Inc. cash on hand
- Fate Therapeutics, Inc. total assets
- Fate Therapeutics, Inc. return on equity (ROE)
- Fate Therapeutics, Inc. return on invested capital (ROIC)
Fate Therapeutics, Inc. (FATE) overview: price, valuation and scorecard
Fate Therapeutics, Inc. earnings: questions and answers
What is Fate Therapeutics, Inc.'s net income?
Fate Therapeutics, Inc. (FATE) reported net income of -$136.32M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$186.26M.
What are the highest and lowest net income figures on record for Fate Therapeutics, Inc.?
Across the 18 fiscal years on record (2008–2025), the highest was -$7.17M in fiscal 2008 and the lowest -$281.72M in fiscal 2022.
How is Fate Therapeutics, Inc.'s net income calculated?
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
Fiscal years are named for the calendar year they end in.
Learn: earnings
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Fate Therapeutics, Inc. (FATE) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/FATE/earnings
Underlying data: the company's filings with the SEC and Yahoo Finance.